founded in 1614  -  top 100 university

Onderzoeksdatabase

Publication

Microbial production of thioether-stabilized peptides

Kuipers, A. 2010 Groningen: s.n.. 125 p.

Research output: ScientificDoctoral Thesis

Documents

  • 00title.pdf

    Final published version, 42 KB, PDF-document

  • 01c1.pdf

    Final published version, 729 KB, PDF-document

  • 02c2.pdf

    Final published version, 726 KB, PDF-document

  • 03c3.pdf

    Final published version, 641 KB, PDF-document

  • 04c4.pdf

    Final published version, 1014 KB, PDF-document

  • 05c5.pdf

    Final published version, 904 KB, PDF-document

  • 06c6.pdf

    Final published version, 442 KB, PDF-document

  • 07c7.pdf

    Final published version, 282 KB, PDF-document

  • 08summ.pdf

    Final published version, 100 KB, PDF-document

  • 09ref.pdf

    Final published version, 200 KB, PDF-document

  • 10sv.pdf

    Final published version, 331 KB, PDF-document

  • 11naw.pdf

    Final published version, 56 KB, PDF-document

  • 12publ.pdf

    Final published version, 66 KB, PDF-document

  • 13complete.pdf

    Final published version, 4 MB, PDF-document

  • Anneke Kuipers
This thesis describes the successful biological production and secretion of thioether-stabilized therapeutic peptides. The lantibiotic modification- and transport enzymes NisBTC and LtnM2T involved in the synthesis of the lantibiotics nisin and lacticin 3147, respectively, were exploited for the introduction of thioether bridges in nonlantibiotic peptides. Importantly, thioether peptides produced via lantibiotic enzymes contain only one isomer (DL), whereas chemically induced thioether formation can lead to several stereo isomers (i.e. DL, LL, LD and DD). Exploiting the nisin modification enzymes NisB and NisC, we were able to demonstrate for the first time the posttranslational introduction of a thioether bridge in a therapeutic peptide, an analog of angiotensin-(1-7). This therapeutic peptide variant has a significantly improved stability and the effectivity of its interaction with the angiotensin-(1-7) receptor is even enhanced. This cyclized analog of angiotensin-(1-7) is therefore a promising therapeutic peptide candidate for treatment of cardiovascular diseases. Moreover, other therapeutic peptides may be thioether-stabilized, using lantibiotic synthesis enzymes. By stabilization, these therapeutic peptides are less sensitive to proteolytic breakdown and accordingly need less frequent administration and/or in a lower dose. In addition, stabilization may allow oral and pulmonary delivery. These delivery ways are more patient-friendly than injection. While there are hundreds of medically highly important therapeutic peptides, the pharmaceutical market of already a single therapeutic peptide can have a size of over a billion dollar. Consequently, stabilization of already FDA-approved therapeutic peptide hormones and development of new effective stabilized peptides has a tremendous potential.
Original languageEnglish
QualificationDoctor of Philosophy
Supervisors/Advisors
Award date10-Sep-2010
Place of PublicationGroningen
Publisher
Print ISBNs9789036744218
Electronic ISBNs9789036744225
StatePublished - 2010

Keywords

  • Proefschriften (vorm), Signaalstoffen, Transporteiwitten, Biosynthese, Stabilisatie, Nisine, Thio-ethers, Peptiden, eiwitten, peptiden, aminozuren

View graph of relations

Download statistics

No data available

ID: 2608460